Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Phase II, single-arm, open-label single center study that assess clinical feasibility and
safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB
NSCLC followed by optional adjuvant treatment upon investigators' decisions.